<DOC>
	<DOCNO>NCT02158988</DOCNO>
	<brief_summary>Patients histological proven gastric cancer ( include cancer esophagogastric junction ( AEG ) ) synchronous peritoneal carcinomatosis , fulfill inclusion exclusion criterion , recruit study . There two treatment group ( A B ) . The chemotherapy apply intravenously group approve treatment gastric cancer . Patients negative unknown HER-2 status administer Epirubicin , Oxaliplatin Capecitabine ( EOX ) . Patients positive HER-2 status treat Cisplatin , Capecitabine Trastuzumab ( CCT ) . The chemotherapy follow surgical cytoreduction group . Patients randomize group B treat intraperitoneal ( abdominal cavity ) chemoperfusion Mitomycin C Cisplatin . Patients group receive 3 cycle postoperative chemotherapy within 4-12 week surgical procedure follow 30 month . If progress tumor detect patient longer treat accord study therapy . Patients group B may get HIPEC intervention without surgical cytoreduction contraindication drug apply exclude .</brief_summary>
	<brief_title>Cytoreductive Surgery ( CRS ) With/Without HIPEC Gastric Cancer With Peritoneal Carcinomatosis</brief_title>
	<detailed_description>The objective trial compare treatment patient peritoneal metastasized gastric cancer include carcinoma AEG ( Adenocarcinoma oesophago-gastric-junction ) without evidence distant metastasis treat neoadjuvant chemotherapy follow cytoreduction intraperitoneal chemoperfusion ( HIPEC ) postoperative chemotherapy ( Group B ) patient treated cytoreduction alone neoadjuvant chemotherapy postoperative chemotherapy ( Group A ) . Hypothesis trial surgical cytoreduction intraperitoneal chemoperfusion ( Group B ) superior cytoreduction alone ( Group A ) term overall survival . The trial design prospective , randomize , open , multicenter parallel group study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<criteria>Histological prove diagnosis peritoneal metastasize gastric cancer include carcinoma AEG No evidence distant metastasis peritoneal carcinomatosis exception Krukenberg Tumors Peritoneal Staging laparoscopy ( explorative laparotomy ) estimation Peritoneal Cancer Index ( PCI ) possibility 80 % tumor reduction cytoreductive surgery Karnofsky Index 70 % well Written informed consent obtain prior commencement trial treatment Other peritoneal metastasis gastric cancer incl . AEG Krukenberg tumor Previous concurrent malignancy , exception adequately treat basal cell carcinoma skin situ carcinoma cervix Any previous chemotherapy radiotherapy , investigational treatment gastric cancer Active systemic infection Patients know interstitial lung disease New York Heart Association classification &gt; 2 Serious cardiac dysrhythmia condition , New York Heart Association classification III IV , congestive cardiac failure cardiac arrhythmia Uncontrolled hypertension ( diastolic blood pressure constantly &gt; 100 mm Hg , systolic blood pressure constantly &gt; 180 mm Hg ) . Inadequate bone marrow function begin trial , define platelet count less &lt; 150 GPT/L neutrophil granulocyte count less &lt; 1.5 GPT/L cardiac function EF &lt; 55 % Inadequate renal function begin trial , define GFR less &lt; 60 ml/min Inadequate liver function begin trial , define Bilirubin &gt; 1.5 time ULN Active vaccination within 6 week prior randomisation Active hepatitis B C infection Female patient pregnant breast feed Fertile female patient ( defined woman le 12month elapse last menstruation ) use acceptable form contraception trial Missing capacity contract contraindication drug use trial Participation another therapeutic clinical trial Persons institutionalise due regulatory action ore court order .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>cancer esophagogastric junction</keyword>
	<keyword>peritoneal carcinomatosis</keyword>
	<keyword>hyperthermic intraperitoneal chemotherapy</keyword>
	<keyword>HIPEC</keyword>
</DOC>